Cutaneous malignant melanoma incidence and mortality trends in Canada: A comprehensive population-based study - 14/01/19
, Ivan V. Litvinov, MD, PhD, FRCPC b, ⁎ Abstract |
Background |
The incidence of cutaneous malignant melanoma (CMM) is on the rise in many parts of the world. However, there is limited knowledge on the epidemiology of CMM in Canada.
Objective |
To conduct a comprehensive population-based study of CMM in Canada.
Methods |
We examined patient clinical and pathologic characteristics as well as the incidence and mortality trends of CMM in Canada using 3 independent population-based registries.
Results |
In total, 72,565 Canadian patients were given CMM diagnoses during 1992-2010; 47.5% were women. Average age at the time of diagnosis was 56.5 years for women and 60.4 years for men. We report a steady increase in CMM incidence and mortality rates in both sexes. The overall incidence rate of CMM in Canada was 12.29 cases/100,000 person-years. We also report important differences in the incidence and mortality rates between Canadian provinces and territories; the highest incidence of this cancer was documented in Nova Scotia and Prince Edward Island.
Limitations |
Data on race, clinical disease stage, and Breslow depth of CMM was not available.
Conclusion |
This study, for the first time, defines the disease burden of CMM in Canada and highlights important longitudinal, geographic, and spatial differences in the distribution of CMM in this country.
Le texte complet de cet article est disponible en PDF.Key words : Canada, CMM, cutaneous malignant melanoma, epidemiology, incidence, lentigo maligna melanoma, mortality, nodular melanoma, risk factors, superficial spreading melanoma
Abbreviations used : ASIR, CCR, CMM, IRR, LRQC, MRR
Plan
| Funding sources: Supported by the Cole Foundation grant (to Dr Litvinov), Fonds de la Recherche en Santé du Québec research grants (34753 and 36769, to Dr Litvinov), and Canadian Dermatology Foundation grants (to Drs Litvinov and Sasseville). |
|
| Conflicts of interest: None disclosed. |
|
| Disclaimer: The interpretation, analysis, and reporting of these data are the sole responsibility of the authors. |
|
| The authors are willing to supply additional material to readers upon request. |
|
| Reprints not available from the authors. |
Vol 80 - N° 2
P. 448-459 - février 2019 Retour au numéro
Article précédent
- Predictors of sentinel lymph node positivity in thin melanoma using the National Cancer Database
- Rosalynn R.Z. Conic, Jennifer Ko, Giovanni Damiani, Pauline Funchain, Thomas Knackstedt, Alok Vij, Allison Vidimos, Brian R. Gastman
- Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study
- Sidsel Arnspang Pedersen, Sigrun Alba Johannesdottir Schmidt, Lisbet Rosenkrantz Hölmich, Søren Friis, Anton Pottegård, David Gaist
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?